Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Piperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL2814299 | 0.96 | — | — | |
| Piperidine SCHEMBL28952742 | 0.87 | ALDH1A1 (0.56) | ALDH1A1CXCR4SMN1; SMN2 | |
| Ethylenediamine SCHEMBL1030825 | 0.84 | — | — | |
| Piperidine SCHEMBL28041935 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2 | |
| Piperidine SCHEMBL7523716 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2 | |
| Piperidine SCHEMBL676507 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2 | |
| Piperidine SCHEMBL3005686 | 0.83 | — | — | |
| Piperidine SCHEMBL27896621 | 0.83 | ALDH1A1 (0.60) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL11775250 | 0.83 | ALDH1A1 (0.60) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL9800122 | 0.83 | ALDH1A1 (0.60) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115895508-A | Adhesive film composition, packaging adhesive film and photovoltaic module | 杭州福斯特应用材料股份有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115011046-A | Anti-fatigue flame-retardant PVC (polyvinyl chloride) plastic boot | 安徽冠泓塑业有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-111892757-A | Water-tree-resistant polyolefin cable material and preparation method thereof | 浙江太湖远大新材料股份有限公司 | 2020-11-06 | — | — | CN | claimed |
| CN-116410637-B | Rare earth antibacterial and antiviral rare earth finishing paint and application thereof | 杭州开物鑫工程技术有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116410637-A | Rare earth antibacterial and antiviral rare earth finishing paint and application thereof | 杭州开物鑫工程技术有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-115895508-A | Adhesive film composition, packaging adhesive film and photovoltaic module | 杭州福斯特应用材料股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115011046-A | Anti-fatigue flame-retardant PVC (polyvinyl chloride) plastic boot | 安徽冠泓塑业有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-108912468-B | Anti-aging bubble film and forming process thereof | 厦门协四方工贸有限公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-111892757-A | Water-tree-resistant polyolefin cable material and preparation method thereof | 浙江太湖远大新材料股份有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2019-02-12 | — | — | US | disclosed |
| CN-109233045-A | A kind of EPE packaging material and preparation method thereof and protective case | 厦门市地隆包装材料有限公司 | 2019-01-18 | — | — | CN | disclosed |
| WO-2003064685-A2 | GENETIC POLYMORPHISMS IN THE PREPROTACHYKININ GENE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
| CN-1426302-A | Method for treating brain, spinal cord and nerve injury | HOFFMANN LA ROCHE (CH) | 2003-06-25 | — | — | CN | disclosed |
| US-20030109417-A1 | Brain, spinal, and nerve injury treament | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2003-06-12 | — | — | US | disclosed |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| EP-1261335-A1 | BRAIN, SPINAL AND NERVE INJURY TREATMENT | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002085458-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. HOFFMAN-LA ROCHE AG (CH) | 2002-10-31 | — | — | WO | disclosed |
| CN-1344337-A | Polyurethane urea elastic fiber and production method thereof | ASAHI CHEMICAL IND (JP) | 2002-04-10 | — | — | CN | disclosed |
| CN-1339074-A | Moisture-absorbing/releasing synthetic fiber and fabric using the same | ASAHI CHEMICAL IND (JP) | 2002-03-06 | — | — | CN | disclosed |
| WO-2001052844-A1 | BRAIN, SPINAL AND NERVE INJURY TREATMENT | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | KLK3, TACR1, TACR2 | PDE4A 1504/4885ALDH1A1 464/4885CXCR4 1099/4885 |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | TACR1, TACR2, NPSR1 | PDE4A 2281/4885ALDH1A1 2796/4885CXCR4 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.